Agios Pharmaceuticals (AGIO) Total Current Liabilities (2012 - 2026)

Agios Pharmaceuticals' Total Current Liabilities history runs 15 years deep, the most recent figure standing at $58.8 million for Q1 2026.

• Quarterly Total Current Liabilities rose 12.37% year-over-year to $58.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $58.8 million (up 12.37% YoY) and the FY2025 annual result came in at $82.2 million, up 1.29% from the prior year.
• Total Current Liabilities was $58.8 million for Q1 2026 at Agios Pharmaceuticals, down from $82.2 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $119.5 million in Q3 2024 and bottomed at $45.1 million in Q1 2023.
• A 5-year average of $64.2 million and a median of $58.8 million in 2026 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities tumbled 52.55% — and 2024, when it surged 104.45%.
• Agios Pharmaceuticals' Total Current Liabilities stood at $62.6 million in 2022, then grew by 8.5% to $68.0 million in 2023, then gained by 19.43% to $81.2 million in 2024, then grew by 1.29% to $82.2 million in 2025, then declined by 28.42% to $58.8 million in 2026.
• Business Quant data shows AGIO's Total Current Liabilities at $58.8 million in Q1 2026, $82.2 million in Q4 2025, and $74.8 million in Q3 2025.